44 related articles for article (PubMed ID: 26331835)
1. Personalized oncology through integrative high-throughput sequencing: a pilot study.
Roychowdhury S; Iyer MK; Robinson DR; Lonigro RJ; Wu YM; Cao X; Kalyana-Sundaram S; Sam L; Balbin OA; Quist MJ; Barrette T; Everett J; Siddiqui J; Kunju LP; Navone N; Araujo JC; Troncoso P; Logothetis CJ; Innis JW; Smith DC; Lao CD; Kim SY; Roberts JS; Gruber SB; Pienta KJ; Talpaz M; Chinnaiyan AM
Sci Transl Med; 2011 Nov; 3(111):111ra121. PubMed ID: 22133722
[TBL] [Abstract][Full Text] [Related]
2. Next-Generation Sequencing in the Clinical Setting Clarifies Patient Characteristics and Potential Actionability.
Bieg-Bourne CC; Millis SZ; Piccioni DE; Fanta PT; Goldberg ME; Chmielecki J; Parker BA; Kurzrock R
Cancer Res; 2017 Nov; 77(22):6313-6320. PubMed ID: 28939679
[TBL] [Abstract][Full Text] [Related]
3.
Gagliardi L; De Vivo M
J Chem Theory Comput; 2024 Jan; 20(2):491. PubMed ID: 38258452
[No Abstract] [Full Text] [Related]
4. The 2024 JCB Early Career Advisory Board.
J Cell Biol; 2024 Jan; 223(1):. PubMed ID: 38108792
[No Abstract] [Full Text] [Related]
5. Introducing the 2023
JACS Au; 2023 Jun; 3(6):1535. PubMed ID: 37388698
[No Abstract] [Full Text] [Related]
6. Towards a Next-Generation Sequencing Diagnostic Service for Tumour Genotyping: A Comparison of Panels and Platforms.
Burghel GJ; Hurst CD; Watson CM; Chambers PA; Dickinson H; Roberts P; Knowles MA
Biomed Res Int; 2015; 2015():478017. PubMed ID: 26351634
[TBL] [Abstract][Full Text] [Related]
7. Non-p.V600E BRAF Mutations Are Common Using a More Sensitive and Broad Detection Tool.
Carter J; Tseng LH; Zheng G; Dudley J; Illei P; Gocke CD; Eshleman JR; Lin MT
Am J Clin Pathol; 2015 Oct; 144(4):620-8. PubMed ID: 26386083
[TBL] [Abstract][Full Text] [Related]
8. Targeted single molecule mutation detection with massively parallel sequencing.
Gregory MT; Bertout JA; Ericson NG; Taylor SD; Mukherjee R; Robins HS; Drescher CW; Bielas JH
Nucleic Acids Res; 2016 Feb; 44(3):e22. PubMed ID: 26384417
[TBL] [Abstract][Full Text] [Related]
9. Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era.
Martin SD; Coukos G; Holt RA; Nelson BH
Ann Oncol; 2015 Dec; 26(12):2367-74. PubMed ID: 26371284
[TBL] [Abstract][Full Text] [Related]
10. The Community Oncology and Academic Medical Center Alliance in the Age of Precision Medicine: Cancer Genetics and Genomics Considerations.
Melas M; Subbiah S; Saadat S; Rajurkar S; McDonnell KJ
J Clin Med; 2020 Jul; 9(7):. PubMed ID: 32640668
[TBL] [Abstract][Full Text] [Related]
11. Multidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in patients with cancer.
Rolfo C; Manca P; Salgado R; Van Dam P; Dendooven A; Ferri Gandia J; Rutten A; Lybaert W; Vermeij J; Gevaert T; Weyn C; Lefebure A; Metsu S; Van Laere S; Peeters M; Pauwels P; Machado Coelho A
ESMO Open; 2018; 3(5):e000398. PubMed ID: 30094075
[TBL] [Abstract][Full Text] [Related]
12. Bioinformatics for precision oncology.
Singer J; Irmisch A; Ruscheweyh HJ; Singer F; Toussaint NC; Levesque MP; Stekhoven DJ; Beerenwinkel N
Brief Bioinform; 2019 May; 20(3):778-788. PubMed ID: 29272324
[TBL] [Abstract][Full Text] [Related]
13. Implementation and utilization of the molecular tumor board to guide precision medicine.
Harada S; Arend R; Dai Q; Levesque JA; Winokur TS; Guo R; Heslin MJ; Nabell L; Nabors LB; Limdi NA; Roth KA; Partridge EE; Siegal GP; Yang ES
Oncotarget; 2017 Aug; 8(34):57845-57854. PubMed ID: 28915716
[TBL] [Abstract][Full Text] [Related]
14. Immunogenomics: using genomics to personalize cancer immunotherapy.
Siniard RC; Harada S
Virchows Arch; 2017 Aug; 471(2):209-219. PubMed ID: 28528510
[TBL] [Abstract][Full Text] [Related]
15. Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery.
Bryce AH; Egan JB; Borad MJ; Stewart AK; Nowakowski GS; Chanan-Khan A; Patnaik MM; Ansell SM; Banck MS; Robinson SI; Mansfield AS; Klee EW; Oliver GR; McCormick JB; Huneke NE; Tagtow CM; Jenkins RB; Rumilla KM; Kerr SE; Kocher JA; Beck SA; Fernandez-Zapico ME; Farrugia G; Lazaridis KN; McWilliams RR
Oncotarget; 2017 Apr; 8(16):27145-27154. PubMed ID: 28423702
[TBL] [Abstract][Full Text] [Related]
16. Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification.
Kamps R; Brandão RD; Bosch BJ; Paulussen AD; Xanthoulea S; Blok MJ; Romano A
Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28146134
[TBL] [Abstract][Full Text] [Related]
17. Use of dedicated gene panel sequencing using next generation sequencing to improve the personalized care of lung cancer.
Kaderbhai CG; Boidot R; Beltjens F; Chevrier S; Arnould L; Favier L; Lagrange A; Coudert B; Ghiringhelli F
Oncotarget; 2016 Apr; 7(17):24860-70. PubMed ID: 27027238
[TBL] [Abstract][Full Text] [Related]
18. Development of a Center for Personalized Cancer Care at a Regional Cancer Center: Feasibility Trial of an Institutional Tumor Sequencing Advisory Board.
Lane BR; Bissonnette J; Waldherr T; Ritz-Holland D; Chesla D; Cottingham SL; Alberta S; Liu C; Thompson AB; Graveel C; MacKeigan JP; Noyes SL; Smith J; Lakhani N; Steensma MR;
J Mol Diagn; 2015 Nov; 17(6):695-704. PubMed ID: 26331835
[TBL] [Abstract][Full Text] [Related]
19. Clinical next generation sequencing to identify actionable aberrations in a phase I program.
Boland GM; Piha-Paul SA; Subbiah V; Routbort M; Herbrich SM; Baggerly K; Patel KP; Brusco L; Horombe C; Naing A; Fu S; Hong DS; Janku F; Johnson A; Broaddus R; Luthra R; Shaw K; Mendelsohn J; Mills GB; Meric-Bernstam F
Oncotarget; 2015 Aug; 6(24):20099-110. PubMed ID: 26015395
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
